Vanguard Capital Management
TRVI icon

Vanguard Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Vanguard Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103M Buy
5,530,675
+552,108
+11% +$8.03M ﹤0.01% 1537
2026
Q1 		$59.4M Buy
+4,978,567
New +$55.7M ﹤0.01% 1768

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management's TRVI Position: Q2 2026 in Review

Vanguard Capital Management increased its Trevi Therapeutics (TRVI) stake by 11% in Q2 2026, buying an estimated $8.03M and bringing the position to 5,530,675 shares worth $103M. The position accounts for ﹤0.01% of the portfolio, ranked #1537.

Vanguard Capital Management first reported a position in TRVI in Q1 2026 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Vanguard Capital Management held 5,530,675 shares of Trevi Therapeutics worth $103M as of Q2 2026.
  • Vanguard Capital Management bought 552,108 Trevi Therapeutics shares in Q2 2026, an estimated $8.03M.
  • Trevi Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1537 holding.
  • Vanguard Capital Management first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 216 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.